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INTRODUCTION: THE IMPORTANCE OF SCALE 
 
Biobanking is essential for science-based health care 
solutions in the 21st century. In order to develop better 
diagnostics, treatments and cures for diseases a deeper 
understanding is needed of genetic and environmental 
pathways causing disease, including mechanisms that 
protect people from becoming ill. Scientific research 
aimed at these issues depends on the availability of a 
broad spectrum of high quality human biological sam-
ples related to health and disease, accompanied by 
clinical, environmental and lifestyle data. Biobanks 
provide these essential resources. 
 In 2006 the Royal Netherlands Academy of Arts 
and Sciences published the results of a foresight study 
on Multifactorial Diseases in the Genomics Era. The 
study focused on scientific opportunities in the causes, 
course and prevention of multifactorial chronic disor-
ders, including the necessary research infrastructure. It 
concluded that in order to be successful an adequate 
amount of good quality biological material and data 
had to be available. It also concluded that existing 
biobanks in the Netherlands and Europe contained suf-
ficient amounts of samples and data to perform more 
detailed analyses. In order to use these, biobanks had 
to be optimized and linked to each other. Data and ma-
terial had to be made mutually comparable, necessi-
tating optimization of phenotype descriptions and data 
registration, as well as standardization of quality and 
storage of biological material. In addition, legal and 
ethical aspects had to be clarified, sufficient funding 
had to be made available and the public had to be 
properly informed. Last but not least, opportunities for 
European collaboration had to be explored (1). 
 In the same year, the European Roadmap for Re-
search Infrastructures was produced by the European 
Strategy Forum on Research Infrastructures (ESFRI). 
This provided a strong impulse for integration of bio-
banks at the European level. Creating a network of 
existing and new biobanks and molecular resources 
was identified as one of the priorities in the field of 
Biomedical and Life Sciences (2). The European 
biobanking community responded to this call in 2007 
and the preparatory phase of the European Biobanking 
and Biomolecular Resources Research Infrastructure 
BBMRI started at the European level in early 2008 
with funding from the European Commission. In its 
preparatory phase (2008-2011), plans were developed 
for a distributed research infrastructure with operatio-
nal units in all participating countries (3). 
 The Dutch National Roadmap for Large-scale Re-
search Facilities which was published later in 2008 
indicated the Dutch node of BBMRI, BBMRI-NL, as 
top-priority (4). It received 22.5 million Euros for its 
initial three year period from NWO, The Netherlands 
Organization for Scientific Research. 
 In this article we outline the Dutch experience in 
biobanking: how a national network of biobanks, 
BBMRI-NL, was set up in the Netherlands and the 





BBMRI-NL unites over 150 Dutch biobanks that con-
tain materials and data from more than 500,000 indivi-
duals. BBMRI-NL does not initiate new biobanks or 
fund maintenance, but focuses on connecting, harmo-
nizing and enriching existing and newly emerging 
biobanks (5). 
 The strength of BBMRI-NL lies in its broad spect-
rum of participating biobanks, ranging from specia-
lized small-scale clinical to large, professionally ope-
rated population-based cohorts. Some of these were 
initiated several decades ago and contain valuable 
longitudinal information. Renowned examples are the 
Netherlands Twin Registry (6) and The Rotterdam 
Study (7). 
 The number of participating biobanks has steadily 
increased over the past two years, underscoring the 
field’s enthusiasm for BBMRI-NL’s approach. Initially 
125 biobanks participated, with a total number of 
395,063 participants. In the summer of 2011 this num-
ber had already increased to more than 150 biobanks 
(+20%) with a total number of 508,334 participants 
(+29%). Most of these biobanks also participate in 
BBMRI’s ‘catalogue of European disease-oriented 
biobanks’ (8) and the international P3G network of 
population-based biobanks (9). All have DNA avai-
lable, many also contain other types of biological 
material such as RNA, plasma, serum, urine or specific 
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Population, development, birth and growth 31 257,059 
Aging (as specific focus; the above also cover older persons, ~30-40%)   3     6,859 
Asthma, allergy 12   26,804 
Cancer 23   38,991 
Cardiovascular 23 101,451 
Dermatology   3       450 
Diabetes, metabolic syndrome, nutrition, storage disorders 10     6,857 
Gastrointestinal and urinary system disorders   7   19,670 
Infection, resistance   8     9,600 
Hemostasis, thrombosis   5     6,760 
Neurological, neurodegenerative   9   13,701 
Rheumatoid disease   5     5,669 
Psychiatric, behavioral 12   14,463 
Total 151 508,334 
 
 
Table 2.  Three major complementary biobanking initiatives in the Netherlands. 
 
Project Aim 
BBMRI-NL Focus on enrichment and harmonization of existing biobanks to increase their scientific, 
economic and societal value, and improve accessibility and utility, e.g. by linking with 
other biobanks. Number of subjects included (2011): over 500,000, up to 20 years follow-
up.Responsible for creating the Dutch national hub of BBMRI. 
PSI Focus on creating common processes and infrastructure in and between University Medical 
Centres (UMCs) highly integrated with the health care process; building a standardized 
clinical sample and data collection as a shared facility between UMCs. 
LifeLines Focus on building a professional, three-generation, population biobank infrastructure with 
national relevance and accessibility, based on a large population (165,000) from the North-
Netherlands, to be followed during 30 years. 
 
 
types of tissue. A general overview of the types of 
biobanks is presented in Table 1. A BBMRI-NL online 
catalogue with basic information on all participating 
biobanks is under construction (10). 
 Since 2007 the Dutch government has contributed 
to building a research infrastructure by awarding major 
grants to the String of Pearls Initiative (PSI) (11) and 
LifeLines (12), which have goals complementary to 
BBMRI-NL. The three initiatives work closely to-
gether. Their aims are described in Table 2. 
 
GOVERNANCE AND ORGANIZATION  
BBMRI-NL is a national consortium, uniting the orga-
nizations that own the abovementioned biobanks. These 
are the eight University Medical Centres (UMCs), PSI, 
the Netherlands Cancer Institute, the National Institute 
for Public Health and the Environment (RIVM), VU 
University Amsterdam and Utrecht University Phar-
maceutical Department. A consortium agreement de-
scribing the strategy and goals of the collaboration, go-
vernance, funding conditions and policies for handling 
issues related to intellectual property was signed by the 
boards of all parties. Scientific and strategic aspects 
are decided upon by a steering committee, with leading 
scientists from all participating organizations as mem-
bers. The committee had monthly meetings in the 
initiating phase. General progress and far-reaching 
strategic decisions are the responsibility of the Board of 
Governors, which consists of members of the boards of 
all participating organizations. 
 The core management of BBMRI-NL, formed by 
the authors of this article together with vice chairs of 
the steering committee Professor Bart Kiemeney 
(UMC St Radboud Nijmegen) and Professor Cisca 
Wijmenga (Groningen UMC), is in charge of day-to-
day operations. A small central office takes care of 
administrative issues and communication, including 
the website, the newsletter ‘Hub’ and the annual ‘Con-
necting Biobanks’ conference. In order to safeguard 
synergy with international biobanking initiatives, an 
International Scientific Advisory Board (ISAB), con-
sisting of international experts and chaired by Profes-
sor Bob Löwenberg (Erasmus MC Rotterdam), counsels 
BBMRI-NL on strategic issues (13). 
 The four main pillars of BBMRI-NL are harmoni-
zation, enrichment, data management and analysis, and 
ethical, legal and societal issues (ELSI). Figure 1 illu-
strates the budget distribution among the four pillars. 
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Table 3.  Example of the content of an imaginary ‘ideal biobank’. 
 
Phenotypes Biomaterials Genotypes and other measurements 
Clinical data DNA DNA sequences 
Anthropometric data Tissue-RNA  Genome Wide Association (GWA) 
Lifestyle data Plasma Transcriptomics (expression data) 
Environmental data  Serum  Proteomics 
Medication Cerebrospinal liquid Metabolomics  
Family history Urine Pharmacogenomics  




Differences in sample and data collection, especially 
concerning phenotype data, can be an obstacle in large-
scale cooperation between biobanks. The disparate 
ways to describe lifestyle aspects is a case in point. 
Differences in sample storage and database structure 
can cause compatibility problems. There may be legal 
differences to be considered as well. For example, the 
permissions obtained from participants may not cover 
the goals of a collaborative study. Harmonization there-
fore requires cooperation on various levels among pro-
fessionals of a different background: scientists and 
clinicians, technicians and ICT professionals, epidemi-
ologists and lawyers. Continuous efforts are needed to 
solve not only current problems, but also to make 
BBMRI-NL 'future proof'. 
 
ENRICHMENT  
The ‘ideal biobank’ (Table 3) does not exist, since bio-
banks are always ‘work in action’. Their content needs 
to be continuously enriched with additional data and 
materials in order to increase their value for research. 
This can be achieved in various ways. Missing mate-
rials or data can be retrieved if other databases that 
include the same patient population exist. Pharmacolo-
gical data for example may be stored in another data-
base, or extra data can be found if the same patients 
participate in a clinical study. Enrichment can also be 
achieved through the application of bioinformatics, 
analyzing existing data to calculate (impute) missing 
information. The successful application of these tech-
niques requires large numbers of samples, again under-
lining the importance of cooperation between biobanks. 
 
DATA MANAGEMENT AND ANALYSIS  
Large efforts have already been made to develop tools 
and techniques for data management and analysis. In 
the near future, even more sophisticated ways to gain 
knowledge from data will be developed. BBMRI-NL 
invests in both hardware and software, and not least in 
talent, to optimise bio-informatics support for national 
and international biobanking and related biomedical 
studies. Through cooperation with the biobanking plat-
form of the Netherlands Bioinformatics Center (NBIC) 
and the European ELIXIR infrastructure, smart solu-
tions for complex problems are shared and put to use.  
 
Figure 1.  Budget distribution. 
 
 
Within the European framework, the various challen-
ges concerning privacy and pseudonymisation are 
being addressed. 
 
ETHICAL, LEGAL AND SOCIETAL ISSUES 
 
The overall public opinion in the Netherlands, for 
instance about further use of human tissue remaining 
after diagnostic procedures, is largely favourable (14). 
BBMRI-NL builds on that trust, showing the benefits 
of biomedical research made possible through bio-
banking. Sensitive issues concerning privacy, the right 
to ‘opt-out’ from participation, various ethical implica-
tions and commercial use of data and materials must 
be addressed in a transparent way. 
 Every participating biobank has its own legal and 
ethical foundation, ensuring participants that their 
rights concerning their donated biospecimens and per-
sonal data will be respected. Large-scale cooperations 
like BBMRI-NL and BBMRI-EU add extra complexi-
ty to the legal and ethical issues that can be raised, for 
instance when combined data from different biobanks 
are scientifically analysed or biological materials are 
transferred abroad. 
 Biobanks share many legal and ethical issues. To 
prevent re-invention of the wheel BBMRI-NL is de-
veloping a legal platform for sharing guidelines and 
experiences, a Dutch ‘Legal Wiki’, following the 
European example. This is an interactive platform for 
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Table 4.  Examples of BBMRI-NL Complementation projects. 
 
Biobank P.I. Aim 
Leiden Longevity Study (21) Professors E.P. Slagboom, 
R.G.J. Westendorp   
(Leiden UMC) 
Enrichment for joined GWAS with BBMRI biobanks on 
different specific phenotypes (metabolomics, glycomics, 
telomere size, longevity) 




Enrichment with total and specific IgE antibody levels against 
airway-allergenes in children and data harmonization with other 
biobanks focusing on asthma and allergy in the Netherlands and 
Europe. 
EPIC-NL (part of the European 
Prospective Investigation into 
Cancer and Nutrition) (23) 
Dr H.B. Bueno-de-
Mesquita (RIVM) 
Renovation of liquid nitrogen tanks, in order to improve safety, 
efficiency and access to samples.  
Dutch Initiative on Crohn and 
Colitis (ICC) (24) 
Dr R.K.Weersma 
(Groningen UMC) 
Optimization of DNA-storage system and sample management 
and harmonization with the String of Pearls Initiative and 
LifeLines. Data harmonization of phenotypic characteristics and 
genotypic enrichment with Immunochip analysis. 
PREVEND (25) Dr R.T. Gansevoort 
(Groningen UMC) 
Enrichment with clinical data and linkage to the Dutch national 
statistics agency. Database harmonization to improve interope-
rability of phenotype and genotype data, applying the minimal 
core data set for biobanks of the international P3G consortium. 
 
 
sharing up-to-date knowledge about regulations, stan-
dards and ‘best practices’ relating to biobanks, coordi-
nated by legal specialist Dr Jasper Bovenberg (15). 
 To help guarantee the protection of both biobank 
participants and scientific progress, BBMRI-NL repre-
sents the Dutch biobanking community in discussions 
on the development of new rules and regulations. For 
instance, a new Dutch law concerning human tissue is 
currently being developed which may greatly affect 
biobanking practice. BBMRI-NL has provided com-
ments regarding the draft law to the Ministry of Health 
(16). Via the committee on research legislation of the 
Dutch federation of Biomedical Scientific Societies 
(COREON) BBMRI-NL has also been involved in the 
update of the ‘Code on good usage of bodily material’ 
(17). This self-regulation code, drawn up by professio-
nals together with patient representatives, has recently 
been adapted to developments in biobanking. 
 Another issue demanding careful legal and ethical 
consideration is whether and how (individual) results 
from biobanking research can and should be shared 
with participants. Building on the experience of Dutch 
and international biobanks, a multidisciplinary team 
led by Professor Cécile Janssens from Erasmus MC 
Rotterdam will develop a joint strategy for return of re-
sults and communication with biobank donors (18,19). 
 
COMPLEMENTATION PROJECTS – SMALL 
BUDGET, HIGH IMPACT  
So what is BBMRI-NL’s approach for enrichment and 
harmonization of 150 Dutch biobanks? Aiming at 
building up a strong research-infrastructure, a project-
based approach was chosen, with two main types of 
projects as building blocks. 
 First, following the establishment of BBMRI-NL, 
and noting the great and diverse need for a rapid boost 
of quality, accessibility and interoperability, a round of 
Complementation projects was conceived. The aim of 
these projects is to strengthen the position of individu-
al Dutch biobanks in collaborative efforts on a national 
and European scale. They focus on harmonization 
and/or enrichment, with a financial scope of 50,000 
Euro per project for a period of one year. At relatively 
low cost and by a very rapid procedure (approximately 
three months), these projects provide a major impetus 
towards the availability of high quality data and 
material for BBMRI. 
 A first group of 43 Complementation projects was 
selected after a call for proposals in 2010, with a total 
budget of 2 million Euros. The aims of these projects 
fall roughly into three categories: (1) genomic enrich-
ment and harmonization; (2) phenotypic enrichment 
and harmonization; and (3) harmonization of sample 
and data storage, management and accessibility. 
 Genomic enrichment is a major aim in 52% of the 
projects, ranging from isolation and quantification of 
DNA in biological material that is already available to 
Genome Wide Association analysis, construction of 
Tissue Micro-Arrays and Whole-exome sequencing. 
An equally important aim (56% of the projects) is 
enrichment and harmonization of phenotypic data, for 
instance by measuring blood-based biomarkers, deter-
mining lifestyle and environmental risk factors, inclu-
ding clinical data and linking to registries, such as 
pharmacy records. The third aim, involving 26% of the 
projects, is harmonization of sample and data storage, 
management and accessibility. Some projects combine 
different aims. A few examples of Complementation 
projects are listed in Table 4. A complete overview 
can be found on the website (20). 
 These projects are hugely popular, due to the low-
threshold/high-need approach, and further rounds are 
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Table 5.  BBMRI-NL Rainbow projects (November 2011). 
 
Number Title Principal Investigators 
1 Genome of the Netherlands (GoNL) Professor C. Wijmenga 
2 Dynamic bioinformatics infrastructures for biobank enrichment Dr M. Swertz 
3 A nation-wide functional genomics infrastructure enabling mechanistic 
insights into complex disease phenotypes 
Dr B. Heijmans, Dr L. Franke, Dr A. 
Isaacs, Dr R. Jansen 
4 Infrastructure for the application of metabolomics technology in 
epidemiology 
Professors P.E. Slagboom, D.I. 
Boomsma, C. van Duijn 
5 A national infrastructure for linkage of biobanks to medical and 
socioeconomic registries: an integrative approach 
Professor J.H. Smit, Dr O.H. Klungel  
6 Towards a joint strategy for the return of results and optimal communication 
with biobank donors 
Professor C. Janssens 
7 Linking tumor tissue samples to Dutch cohort studies for advancing 
molecular pathological epidemiology 
Professor P.A. van den Brandt 
8 Dutch National Tissue Portal (DNTP) Professor G.A. Meijer, Dr F.J. van 
Kemenade, Dr L.I.H. Overbeek 
9 Nutritional enrichment and harmonization of the Dutch Cohort Infrastructure Dr H.B. Bueno-de-Mesquita  
 
 
foreseen. The success is partly due to the virtual lack 
of funding for this type of infrastructural upgrading 
from other sources, since it is not directly linked to 
specific research questions. Nevertheless, a number of 
scientific publications as a direct result of these invest-
ments are already underway and we expect many more, 
including possible clinical applications. 
 Taken together these relatively small projects have 
a major qualitative and quantitative impact, enriching 
and harmonizing over 300,000 samples in over 40 
Dutch biobanks, all part of the national infrastructure 




RAINBOW PROJECTS – A NATIONWIDE 
APPROACH 
 
BBMRI-NL Rainbow projects aim at harmonization 
and enrichment, not of individual biobanks, but on a 
national scale. The financial scope of these collabora-
tive efforts of biobanks and research centres generally 
falls between one to two million Euros. 
 An example is ‘Genome of the Netherlands’ (GoNL). 
The aim of this project, which started in 2010, is to 
determine the genetic profile of the Dutch indigenous 
population by DNA-sequencing of 750 Dutch indivi-
duals, 250 trios of two parents and an (adult) child. 
GoNL is a consortium of five UMC’s, led by Professor 
Cisca Wijmenga from Groningen. The sequencing work 
is done by BGI Hong Kong. The trio-based design cou-
pled with intermediate coverage sequencing enables 
the generation of a high-quality reference panel for 
imputation in Dutch GWAS data sets, the development 
of novel tools for family-based sequencing studies, and 
an unprecedented level of accuracy of the haplotypes 
for population genetic analyses. 
 A second Rainbow project ‘Dynamic Bioinforma-
tics’, which is closely linked to GoNL, aims to build a 
national infrastructure for data management and 
analysis by harmonizing bioinformatics methods, 
databases, software and formats. Dutch biobanks are 
enriched with new models, software and tools for next 
generation sequencing data with scalable data archives, 
flexible and large scale processing pipelines and easy-
to-connect systems for data exchange. Five UMC’s are 
involved in this project, as well as the Netherlands 
Bioinformatics centre (NBIC) and the String of Pearls 
Initiative. Project leader is Dr Morris Swertz from 
Groningen UMC. The project is interlinked with Euro-
pean and global efforts such as P3G, EBI, ELIXIR, 
ENGAGE and BioSHaRE-EU. 
 Other Rainbow projects aim, for instance, at linkage 
of biobanks to medical and socio-economic registries, 
at building an infrastructure for harmonization, proces-
sing and analysis of metabolomics data from different 
platforms in biobank material or at creating nation-
wide functional genomics database with genome-wide 
genetic, transcriptomic and epigenomic data in Dutch 





BBMRI’s next challenge will be to consolidate the 
infrastructure at the European level by becoming a 
European Research Infrastructure Consortium (ERIC) 
(26). The Dutch government has committed itself to 
becoming a partner in this European legal entity by 
signing a Memorandum of Understanding (MoU). 
 Another major challenge will be to facilitate the 
development of clinical applications. Although in ge-
neral Dutch citizens and patients are highly motivated 
to participate in biobanking efforts for scientific and 
medical purposes, they show a much more critical atti-
tude towards providing material and data to commerci-
al parties (14). A transparent policy is essential to safe-
guard the trust of patients and citizens (27) BBMRI-
NL will follow the concept of ‘Expert Centres’ which 
has been developed by BBMRI at the European level 
and aims at establishing public-private partnerships in 
the pre-competitive, not-for profit field. 
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